This site is intended for healthcare professionals outside the United States

CAR-T CELL THERAPIES IN FL/DLBCL

Expert-led conference insights from the 2021 ASCO Annual Meeting and EHA 2021

On-demand.

Panel discussion: FL/DLBCL

Recorded Thursday 17th June 2021

Please join Prof. Dr. Marion Subklewe (Gene Center, Munich, Germany) and an esteemed panel of experts for a webinar where the key data and findings from the CAR-T cell therapy in FL/DLBCL scientific sessions presented at the 2021 ASCO Annual Meeting and EHA 2021 congresses are discussed.

Time	Section Title
0:00 – 2:45	Introduction
2:46 – 17:03	Real-world evidence
17:04 – 28:50	Real-world data in DLBCL: infections, G-CSF and response to COVID-19 vaccination
28:51 – 41:46	CAR-T cell updates from ZUMA and ELARA trials
41:47 – 54:34	Novel CAR-T design
54:34 – 1:07:57	‘Off-the-shelf’ therapies

Program chair.

Prof. Dr. Marion Subklewe

Gene Center, Munich, Germany

Marion Subklewe is Head of the Laboratory for Translational Cancer Immunotherapy at the Gene Center, Munich and Professor of Internal Medicine at Ludwig Maximilian University of Munich, Germany. She studied medicine at University Hospital Tübingen and completed her postdoctoral fellowship at Rockefeller University in New York.

Professor Subklewe is current Head of the Immunotherapy Program in Haematology and the CAR-T Program at University Hospital Munich, Founder and Speaker of the national “Harmonize MRD Flow” Consortium and member of the ELN Working group on MRD. She is also active in clinical research and has been Principal Investigator in 3 I-IT trials in AML and ALL, as well as in over 30 oligo- and multicentric Phase I trials in leukaemia and lymphoma. In recognition of her work, Professor Subklewe has received numerous honours and awards including the EHA Educational Presentation and ASH Abstract Achievement Awards.

Faculty.

Prof. Irit Avivi
Prof. Marie Jose Kersten
Dr. Reuben Benjamin
Dr. Maeve O’Reilly

Prof. Irit Avivi, MD

Tel Aviv Institute of Hematology and Bone Marrow Transplantation,
Tel Aviv Medical Center

Prof. Irit Avivi serves as the Director of the Hematology division at Sourasky Tel Aviv Medical Center. She was trained in adult hemato-oncology at Rambam Medical Center and completed a fellowship in lymphoma and myeloma at London University College Hospitals.

Prof. Avivi’s major research and clinical expertise are in prognostication and treatment of myeloma and lymphoma, including the employment of immune-modulating strategies (e.g. dendritic cell fusion vaccine, regulatory cell depletion and CAR-T cells) and in managing hematological cancers during pregnancy.

Prof. Avivi has extensive international collaborations with multiple groups in Europe and the USA and is highly involved in many pivotal, phase I–IV clinical studies including CAR-T cell therapy in myeloma and lymphoma. In addition, she has a wide experience in initiating and conducting investigator-initiated studies involving multiple centers, exploring new therapeutic approaches for myeloma and lymphoma, and assessment of biomarkers.

She has over 160 scientific publications, is a frequently invited speaker and has won several awards for her immune-translational research in myeloma and lymphoma.

Prof. Marie José Kersten, MD, PhD

Amsterdam UMC

Marie José Kersten is Professor of Hematology in the Department of Hematology at Amsterdam UMC, Amsterdam. B-cell malignancies are the main focus of research in this department, which together with the Departments of Pathology and Experimental Immunology form the basis for the Lymphoma and Myeloma Center Amsterdam (LYMMCARE Institute).

Prof. Marie José Kersten is involved in several research projects and she is the Principal Investigator for several phase I/II clinical trials focusing on the biology and treatment of non-Hodgkin lymphoma, Waldenstrom’s macroglobulinemia and Hodgkin lymphoma. She is Chair of the European Hematology Association Scientific Working Group Lymphoma and a co-founder and Chair of the Lunenburg Lymphoma Phase I/II Consortium (LLPC). The main focus of the LLPC is to perform early clinical trials (from first-in-human to early phase II trials) in patients with lymphoma. She is also an active member of the Lunenburg Lymphoma Biomarker Consortium (LLBC), the European Waldenstrom’s Macroglobulinemia Consortium (EWMC) and the Haemato-Oncology Foundation for Adults in The Netherlands (HOVON) Myeloma Working Party.

Dr. Reuben Benjamin, MBBS, FRCPath, PhD

King’s College Hospital, London

Dr. Reuben Benjamin is a hemato-oncologist with expertise in CAR-T cell therapy. He trained at University College Hospital, London, and was a visiting investigator at Memorial Sloan Kettering Cancer Center, New York, where he undertook research in CAR-T cells for leukemia and myeloma. He currently oversees the CAR-T cell programme and plasma cell disorder service at King’s College Hospital, London, and leads a research group focused on allogeneic CAR-T cells for hematological malignancies.

Dr. Maeve O'Reilly, MD

University College London Hospital

Dr. Maeve O'Reilly is a T-cell Immunotherapy Consultant at University College London Hospital (UCLH). UCLH has a large T-cell Immunotherapy department with an expanding portfolio of academic and commercial T-cell clinical trials. Dr. O’Reilly has completed an MD (Res) at University College London. Her research focused on the optimization of CAR-T cell manufacture, T-cell apheresis for the UCL academic CAR-T clinical trials and clinical service development for the delivery of T-cell immunotherapy.

Agenda.

Twitter polls.

Where should polatuzumab vedotin-based therapy be placed?

What is the largest issue regarding 'off-the-shelf' CAR-T cell products?

When should granulocyte colony-stimulating factors be applied after CAR-T cell therapy?

Are we heading for approval of all CAR-T cell therapies in follicular lymphoma?

Can we combat the obstacles in allogenic CAR T therapy and eventually move to an off-the-shelf product?

What are you most interested in hearing about CAR-T cell therapy?

Funding.

The content and faculty for this program have been independently developed and/or selected by Springer Healthcare. Novartis Pharmaceutical Corporation provided unconditional funding and as such had no involvement with, or influence on the content and selection of faculty. The content is not intended for use by healthcare professionals in the US. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.

Registration

* Required for CME certification

Login

Reset Password